At GSK responsible business is how we do business. Our mission is to improve the quality of human life by enabling people to do more, feel better, live longer.
To achieve this mission we are adapting our business model and pursuing a strategy that delivers sustainable performance through innovation and expanding access, driven by our values.
We report key information on our approach to responsible business alongside our financial performance within the Annual Report. Our Responsible Business Supplement provides a greater level of context and detail of our work against our responsible business commitments.
Read on below and click on the respective areas of responsibility to explore more on our global GSK website.
How we operate is just asSir Andrew Witty, CEO, GSK
important to us as delivering financial performance."
In 2012 we developed 23 forward-looking commitments across the four areas of our responsible business approach. They aim to address global health needs and are aligned with our strategic priorities and our values.
For information on how we are progressing against our commitments in each of our four areas click on the links below:
How we are developing innovative products and improving access to healthcare for patients around the world.
How we are embedding our values throughout our business, including the ways we research, develop, sell and market our products.
How we create an inspiring and supportive work environment that encourages our employees to develop their capabilities and achieve their best.
How we are managing the environmental impacts of our operations and products to reduce carbon emissions, water use and waste.
We have a robust structure in place to ensure the approach we take on corporate responsibility is appropriate. Our board-level Corporate Responsibility Committee (CRC) has overall oversight and sits within a clear organisational structure that ensures accountability.
We engage with a wide range of stakeholders through: day-to-day interactions with customers; engagement with governments and patient advocacy groups; regular dialogue with employees; suppliers, partners and investors.
Dialogue with these stakeholders enables us to understand how our business may affect – or be affected – by them. Their feedback helps us to identify and prioritise important issues and develop responses that are in the best interests of society, as well as our shareholders.